Patent policy changes proposed by USPTO and FDA would leave patients behind

Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal of improving health care affordability for Americans, but we disagree that changes are needed to U.S. patent law and policy to increase generic and biosimilar competition.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Patents Intellectual Property Source Type: news